Trial Profile

A Phase 1a Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Advanced Malignant Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 322 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Innovent Biologics

Most Recent Events

06 Oct 2023 Status changed from recruiting to completed.
28 Apr 2022 Planned number of patients changed from 45 to 51.
28 Apr 2022 Planned End Date changed from 1 Dec 2022 to 29 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com